FXR Agonist

FXR Agonists (47):

Cat. No.	Product Name	Effect	Purity

HY-12222

Obeticholic acid	Agonist	≥98.0%
Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy.

HY-50108

GW 4064	Agonist	99.61%
GW 4064 is a potent FXR agonist with an EC₅₀ of 65 nM.

HY-10626

T0901317	Agonist	99.93%
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα. T0901317 activates FXR with an EC₅₀ of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.

HY-109083

Cilofexor	Agonist	99.82%
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.

HY-10912

Fexaramine	Agonist	99.24%
Fexaramine is a potent and selective FXR agonist with an EC₅₀ of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors.

HY-107418

Tropifexor	Agonist	99.35%
Tropifexor (LJN452) is a highly potent agonist of FXR with an EC₅₀ of 0.2 nM.

HY-12434

INT-767	Agonist	99.81%
INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC₅₀s of 30 and 630 nM, respectively.

HY-50911

Turofexorate isopropyl	Agonist	99.76%
Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC₅₀ of 4 nM.

HY-109197

Vonafexor	Agonist	99.32%
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research.

HY-109096

Nidufexor	Agonist	99.67%
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH).

HY-100443A

trans-PX20606	Agonist	99.24%
PX20606 trans racemate (PX-102 trans racemate) is a FXR agonist with EC₅₀s of 32 and 34 nM for FXR in FRET and M1H assay, respectively.

HY-147296

Omesdafexor	Agonist	99.65%
Omesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer，promote intestinal antimicrobial function, barrier function and inhibit inflammation .

HY-151932

FXR agonist 3	Agonist
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level.

HY-134988

EDP-305	Agonist
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research.

HY-153525

FXR agonist 5	Agonist	99.83%
FXR agonist 5 (compound 1) is a FXR agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation.

HY-153114

HEC96719	Agonist	98.01%
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis.

HY-12222S1

Obeticholic Acid-d₄	Agonist	≥98.0%
Obeticholic Acid-d₄ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].

HY-135399

Tauro-obeticholic acid	Agonist	≥98.0%
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.

HY-135400

Glyco-Obeticholic acid	Agonist	≥98.0%
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist.

HY-101273

BAR502	Agonist	99.53%
BAR502 is a dual FXR and GPBAR1 agonist with IC₅₀ values of 2 μM and 0.4 μM, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.